BR112014004008A2 - estrogen receptor ligands and application thereof - Google Patents

estrogen receptor ligands and application thereof

Info

Publication number
BR112014004008A2
BR112014004008A2 BR112014004008A BR112014004008A BR112014004008A2 BR 112014004008 A2 BR112014004008 A2 BR 112014004008A2 BR 112014004008 A BR112014004008 A BR 112014004008A BR 112014004008 A BR112014004008 A BR 112014004008A BR 112014004008 A2 BR112014004008 A2 BR 112014004008A2
Authority
BR
Brazil
Prior art keywords
application
estrogen receptor
receptor ligands
ligands
estrogen
Prior art date
Application number
BR112014004008A
Other languages
Portuguese (pt)
Inventor
C Coss Christopher
Dalton James
S Steiner Mitchell
Original Assignee
Gtx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/215,679 external-priority patent/US9427418B2/en
Application filed by Gtx Inc filed Critical Gtx Inc
Priority claimed from PCT/US2012/052141 external-priority patent/WO2013043304A1/en
Publication of BR112014004008A2 publication Critical patent/BR112014004008A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pain & Pain Management (AREA)
BR112014004008A 2009-02-23 2012-08-23 estrogen receptor ligands and application thereof BR112014004008A2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15470709P 2009-02-23 2009-02-23
US16898309P 2009-04-14 2009-04-14
US26166909P 2009-11-16 2009-11-16
US13/215,679 US9427418B2 (en) 2009-02-23 2011-08-23 Estrogen receptor ligands and methods of use thereof
PCT/US2012/052141 WO2013043304A1 (en) 2009-02-23 2012-08-23 Estrogen receptor ligands and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112014004008A2 true BR112014004008A2 (en) 2017-03-28

Family

ID=42634248

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014004008A BR112014004008A2 (en) 2009-02-23 2012-08-23 estrogen receptor ligands and application thereof

Country Status (10)

Country Link
EP (1) EP2398322A4 (en)
JP (1) JP5611991B2 (en)
KR (3) KR20150135547A (en)
CN (1) CN102413692B (en)
BR (1) BR112014004008A2 (en)
CA (1) CA2753436C (en)
IL (1) IL214805A0 (en)
MX (1) MX340753B (en)
RU (1) RU2543339C2 (en)
WO (1) WO2010096801A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
WO2010141630A1 (en) * 2009-06-03 2010-12-09 University Of Southern California Compositions and methods for treatment of cancer by disrupting the lh/lhr signaling pathway
JP2014524479A (en) * 2011-08-23 2014-09-22 ジーティーエックス・インコーポレイテッド Estrogen receptor ligands and methods of use thereof
WO2013142390A1 (en) * 2012-03-21 2013-09-26 Gtx, Inc. Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
WO2014039820A1 (en) * 2012-09-07 2014-03-13 Gtx, Inc. Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
WO2023220117A1 (en) * 2022-05-10 2023-11-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of treating dilated cardiomyopathy and heart failure

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020192310A1 (en) * 2001-02-02 2002-12-19 Bland Jeffrey S. Medical composition for managing hormone balance
US20060287282A1 (en) * 2001-06-25 2006-12-21 Steiner Mitchell S Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof
US7601739B2 (en) * 2003-08-08 2009-10-13 Virgina Commonwealth University Compounds having antiestrogenic and tissue selective estrogenic properties, and compounds with anti-androgenic properties for treatment of prostate cancer and androgen receptor dependent diseases
US8546451B2 (en) * 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
EA201500845A1 (en) * 2005-11-28 2016-04-29 Джи Ти Икс, ИНК. AGENTS CONNECTING WITH NUCLEAR RECEPTORS
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents

Also Published As

Publication number Publication date
WO2010096801A1 (en) 2010-08-26
EP2398322A4 (en) 2012-12-05
CN102413692B (en) 2015-01-07
CA2753436C (en) 2016-05-24
KR20130101146A (en) 2013-09-12
MX2011008879A (en) 2012-04-30
MX340753B (en) 2016-07-25
JP2012518654A (en) 2012-08-16
KR20150135547A (en) 2015-12-02
AU2010215809A1 (en) 2011-09-22
JP5611991B2 (en) 2014-10-22
RU2011137324A (en) 2013-03-27
CA2753436A1 (en) 2010-08-26
KR101458539B1 (en) 2014-11-10
CN102413692A (en) 2012-04-11
KR20110131227A (en) 2011-12-06
IL214805A0 (en) 2011-11-30
RU2543339C2 (en) 2015-02-27
EP2398322A1 (en) 2011-12-28

Similar Documents

Publication Publication Date Title
BR112014004008A2 (en) estrogen receptor ligands and application thereof
BRPI1009455A2 (en) anti-c40 antibodies and uses thereof
BRPI0912198A2 (en) anti-fn14 antibodies and uses thereof
BRPI0921663A2 (en) diaplay device
DE602008000955D1 (en) Template-based overlap detection
BRPI0918868A2 (en) nmda receptor modulators and uses thereof
BR112012001260A2 (en) epsilon-polylysine conjugates and their use
BRPI1008193A2 (en) triggered location services
BRPI0909644A2 (en) photo-epilation device
BRPI0919074A2 (en) multi-touch object inertia stimulus
BRPI0919539A2 (en) peripheral opioid receptor antagonists and their uses
BRPI1010024A2 (en) aminopyrrolidinone derivatives and their use
DK2434871T3 (en) Bee-mounted spreading device
BRPI1008752A2 (en) alkyl starch compounds and uses thereof
BR112012010242A2 (en) heteroarylpiperidine and heteroarylpiperazine derivatives
BRPI0908548A2 (en) boom support
BR112012014770A2 (en) ethinyl derivatives
FR2953228B1 (en) SCREEN SCREEN
DK2486010T3 (en) Estrogen receptor ligands
BRPI0823275A2 (en) Induction device
BRPI0910253A2 (en) 2-aminoquinoline derivatives
DE502008001891D1 (en) edge material
BRPI0823295A2 (en) Induction device
IT1392801B1 (en) COVERED SET AND COVERED COVER
FI20085637A0 (en) Mounting device and arrangement

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2476 DE 19-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.